Skip to ContentSkip to Navigation
How to find us E. Meijer

Research interests

Esther Meijer is an internist-nephrologist with specific interest in Autosomal Dominant Polycystic Kidney Disease (ADPKD). At the University Medical Center Groningen (UMCG), she combines clinical work with research. She sees approximately 250 ADPKD patients per year and is study coordinator of a Dutch national observational cohort of ADPKD patients. Her current research focuses on markers of disease progression, and improving treatment in ADPKD. In 2019, she received an early career grant from the Dutch Kidney Foundation to investigate improvement of treatment with a vasopressin V2 receptor antagonist, by decreasing the adverse events. 


No Change in Nocturia After NOCTURNE

Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations

Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease

Somatostatin in renal physiology and autosomal dominant polycystic kidney disease

Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study

Urine-to-plasma urea ratio, as surrogate marker for urine concentrating capacity, is associated with disease progression in adpkd

Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease

Read more